These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 32496434

  • 1. Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
    Dibbern ME, Bullock TN, Jenkins TM, Duska LR, Stoler MH, Mills AM.
    Am J Surg Pathol; 2020 Sep; 44(9):1184-1191. PubMed ID: 32496434
    [Abstract] [Full Text] [Related]

  • 2. PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy.
    Chinn Z, Stoler MH, Mills AM.
    Histopathology; 2019 Jan; 74(2):256-268. PubMed ID: 30067880
    [Abstract] [Full Text] [Related]

  • 3. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.
    Yang W, Song Y, Lu YL, Sun JZ, Wang HW.
    Immunology; 2013 Aug; 139(4):513-22. PubMed ID: 23521696
    [Abstract] [Full Text] [Related]

  • 4. Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.
    Curley J, Conaway MR, Chinn Z, Duska L, Stoler M, Mills AM.
    Mod Pathol; 2020 Jun; 33(6):1182-1192. PubMed ID: 32139873
    [Abstract] [Full Text] [Related]

  • 5. [Current events in immunotherapy for upper aerodigestive tract cancer].
    Outh-Gauer S, Le Tourneau C, Broudin C, Scotte F, Roussel H, Hans S, Mandavit M, Tartour E, Badoual C.
    Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
    [Abstract] [Full Text] [Related]

  • 6. Indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase expression in HPV infection, SILs, and cervical cancer.
    Venancio PA, Consolaro MEL, Derchain SF, Boccardo E, Villa LL, Maria-Engler SS, Campa A, Discacciati MG.
    Cancer Cytopathol; 2019 Sep; 127(9):586-597. PubMed ID: 31412167
    [Abstract] [Full Text] [Related]

  • 7. PD-L1 Expression in HPV-associated Versus HPV-independent Invasive Vulvar Squamous Cell Carcinoma.
    Bui CM, Medeiros F, Azimpouran M, Venturina M, Balzer B.
    Int J Gynecol Pathol; 2024 Jul 01; 43(4):405-413. PubMed ID: 38303111
    [Abstract] [Full Text] [Related]

  • 8. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.
    Yang W, Lu YP, Yang YZ, Kang JR, Jin YD, Wang HW.
    J Obstet Gynaecol Res; 2017 Oct 01; 43(10):1602-1612. PubMed ID: 28833798
    [Abstract] [Full Text] [Related]

  • 9. Nocardia Rubra Cell Wall Skeleton Up-Regulates T Cell Subsets and Inhibits PD-1/PD-L1 Pathway to Promote Local Immune Status of Patients With High-Risk Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia.
    Chen W, Zhang Y, Zhao C, Shao S, Zhang Y, Li X, Bai X, Guo Q, Liu Q, Tang J, Zhang L.
    Front Immunol; 2020 Oct 01; 11():612547. PubMed ID: 33552075
    [Abstract] [Full Text] [Related]

  • 10. MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors.
    Dusenbery AC, Maniaci JL, Hillerson ND, Dill EA, Bullock TN, Mills AM.
    Am J Surg Pathol; 2021 May 01; 45(5):701-707. PubMed ID: 33739790
    [Abstract] [Full Text] [Related]

  • 11. Programmed death-ligand 1 (PD-L1) expression in cervical intraepithelial neoplasia and cervical squamous cell carcinoma of HIV-infected and non-infected patients.
    Brito MJ, Sequeira P, Quintas A, Silva I, Silva F, Martins C, Félix A.
    Virchows Arch; 2024 Mar 01; 484(3):507-516. PubMed ID: 37341812
    [Abstract] [Full Text] [Related]

  • 12. Comparative transcriptomic profiling in HPV-associated cervical carcinogenesis: Implication of MHC class II and immunoglobulin heavy chain genes.
    Balasubramaniam SD, Wong KK, Oon CE, Balakrishnan V, Kaur G.
    Life Sci; 2020 Sep 01; 256():118026. PubMed ID: 32615187
    [Abstract] [Full Text] [Related]

  • 13. PD-L1 receptor expression in vulvar carcinomas is HPV-independent.
    Choschzick M, Gut A, Fink D.
    Virchows Arch; 2018 Oct 01; 473(4):513-516. PubMed ID: 29736798
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.
    Dyer BA, Zamarin D, Eskandar RN, Mayadev JM.
    J Natl Compr Canc Netw; 2019 Jan 01; 17(1):91-97. PubMed ID: 30659133
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Patients with usual vulvar intraepithelial neoplasia-related vulvar cancer have an increased risk of cervical abnormalities.
    de Bie RP, van de Nieuwenhof HP, Bekkers RL, Melchers WJ, Siebers AG, Bulten J, Massuger LF, de Hullu JA.
    Br J Cancer; 2009 Jul 07; 101(1):27-31. PubMed ID: 19513077
    [Abstract] [Full Text] [Related]

  • 18. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
    Miyauchi S, Sanders PD, Guram K, Kim SS, Paolini F, Venuti A, Cohen EEW, Gutkind JS, Califano JA, Sharabi AB.
    Cancer Res; 2020 Feb 15; 80(4):732-746. PubMed ID: 31848196
    [Abstract] [Full Text] [Related]

  • 19. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA.
    J Clin Oncol; 2018 Apr 01; 36(10):942-950. PubMed ID: 29394125
    [Abstract] [Full Text] [Related]

  • 20. HPV subtypes and immunological parameters of cervical cancer in Iceland during two time periods, 1958-1960 and 1995-1996.
    Mikaelsdottir EK, Benediktsdottir KR, Olafsdottir K, Arnadottir T, Ragnarsson GB, Olafsson K, Sigurdsson K, Kristjansdottir GS, Imsland AK, Ogmundsdottir HM, Rafnar T.
    Gynecol Oncol; 2003 Apr 01; 89(1):22-30. PubMed ID: 12694650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.